3-硝基苯甲酸 | 125-30-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 中文名称: 3-硝基苯甲酸
• 中文别名: 盐酸乙基吗啡
• 英文名称: Ethylmorphinhydrochloriddihydrat
• 英文别名: 3-O-ethylmorphine hydrochloride；Ethylmorphine hydrochloride；3-ethoxy-4,5α-epoxy-17-methyl-morphin-7-en-6α-ol; hydrochloride；3-Aethoxy-4,5α-epoxy-17-methyl-morphin-7-en-6α-ol; Hydrochlorid；ethylmorphine hydrochloride；Dionin*HCl；(4R,4aR,7S,7aR,12bS)-9-ethoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol;hydron;chloride
• CAS: 125-30-4
• 化学式: C₁₉H₂₃NO₃*ClH
• 分子量: 349.857
• InChiKey: ZPPBASOODYCKDP-YZZSNFJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.31
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  41.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• External preparation for skin diseases containing nitroimidazole
  申请人：——

  公开号：US20030092754A1

  公开（公告）日：2003-05-15

  An external preparation for skin disease which comprises a nitroimidazole derivative represented by the following formula (I): 1 wherein R 1 , R 3 and R 4 may be the same or different and represent a hydrogen atom, a nitro group, a lower alkyl group, a substituted lower alkyl group, a lower alkenyl group, or a substituted lower alkenyl group; and R 2 represents a hydrogen atom, a lower alkyl group, a substituted lower alkyl group and a lower alkenyl group or a substituted lower alkenyl group, provided that any one of R 1 , R 3 and R 4 is a nitro group.

  一种外用制剂，用于皮肤疾病，包括以下式(I)所代表的硝基咪唑衍生物：1其中R1、R3和R4可以相同也可以不同，并表示氢原子、硝基、低烷基、取代的低烷基、低烯基或取代的低烯基；R2表示氢原子、低烷基、取代的低烷基和低烯基或取代的低烯基，只要R1、R3和R4中的任何一个是硝基。
• Amphiphilic or lipophilic polar functionalized fullerenes and their uses
  申请人：Zhou Zhiguo

  公开号：US20080213324A1

  公开（公告）日：2008-09-04

  Described herein are synthetically modified fullerene molecules, wherein the fullerene is preferably ellipsoid in shape with an equatorial band and two opposing poles, comprising an adduct at one or both poles, at least one adduct being a hydrophobic chemical moiety capable of anchoring the fullerene on or in a lipid membrane.

  本文介绍了合成改性富勒烯分子，其中富勒烯最好呈椭球形状，具有一个赤道带和两个相对的极点，包括一个或两个极点的加合物，至少一个加合物是一种疏水化学基团，能够将富勒烯锚定在或在脂质膜中。
• Controlled release pharmaceutical composition
  申请人：Euroceltique S.A.

  公开号：EP0214735A1

  公开（公告）日：1987-03-18

  A solid, controlled release, pharmaceutical composition comprising a drug and an anionic surfactant, incorporated in a matrix comprising a hydrophilic polymer, wherein the drug is either an acid addition salt of an organic base or a quaternary ammonium salt, provided that,. the organic base is not propranolol or chlorpheniramine. Preferably the drug is an acid addition salt of an organic amine, the surfactant is a sulphosuccinate and the polymer is a water-soluble hydroxyalkyl cellulose ether.

  一种固体控释药物组合物，由药物和阴离子表面活性剂组成，掺入由亲水性聚合物组成的基质中，其中药物为有机碱的酸加成盐或季铵盐，条件是：有机碱不是普萘洛尔或氯苯那敏。 药物最好是有机胺的酸加成盐，表面活性剂是磺基琥珀酸酯，聚合物是水溶性羟烷基纤维素醚。
• Medicated plasters
  申请人：NITTO DENKO CORPORATION

  公开号：EP0387751A2

  公开（公告）日：1990-09-19

  Medicated plasters composed of a flexible support and a pressure-sensitive adhesive layer laminated thereon, in which said pressure-sensitive adhesive layer has an exposed surface with pH of 7 or higher and contains one of the following three components: (i) a basic physiologically active agent and an acidic substance, (ii) a salt of a basic physiologically active agent and a basic substance, and (iii) a basic physiolosically active agent and a salt of a basic physiolosically active agent.

  药用膏药，由柔性支架和层压在其上的压敏胶层组成，其中所述压敏胶层的外露表面 pH 值为 7 或更高，并含有以下三种成分之一： (i) 碱性生理活性剂和酸性物质、 (ii) 碱性生理活性剂和碱性物质的盐，以及 (iii) 碱性生理活性剂和碱性生理活性剂的盐。
• PERCUTANEOUSLY ABSORBABLE COMPOSITION OF MORPHINE HYDROCHLORIDE
  申请人：Morimoto, Yasunori

  公开号：EP0480054A1

  公开（公告）日：1992-04-15

  A percutaneously absorbable preparation comprising a narcotic analgesic of a low percutaneous absorbability such as morphine hydrochloride or sulfate, a nonnarcotic analgesic such as eptazocine hydrobromide, a percutaneous absorption promoter, and a percutaneous absorption promoter aid.

  一种可经皮吸收的制剂，包括一种经皮吸收率较低的麻醉性镇痛药（如盐酸吗啡或硫酸吗啡）、一种非麻醉性镇痛药（如氢溴酸依帕佐辛）、一种经皮吸收促进剂和一种经皮吸收促进剂辅助剂。